127 related articles for article (PubMed ID: 19270153)
41. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
[TBL] [Abstract][Full Text] [Related]
42. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
Vieira MC; Kumar RN; Jansen JP
HIV Clin Trials; 2011; 12(4):175-89. PubMed ID: 22044854
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
44. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
[TBL] [Abstract][Full Text] [Related]
45. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Karlström O; Josephson F; Sönnerborg A
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
[TBL] [Abstract][Full Text] [Related]
46. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
[TBL] [Abstract][Full Text] [Related]
47. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
48. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
[TBL] [Abstract][Full Text] [Related]
49. PI monotherapy effective as maintenance.
AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
[No Abstract] [Full Text] [Related]
50. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
[TBL] [Abstract][Full Text] [Related]
51. Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.
Gardner EM; Melendez AG; Astiz M; Bray K
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(1):34-9. PubMed ID: 21972263
[TBL] [Abstract][Full Text] [Related]
52. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
Wilkin TJ; McKinnon JE; DiRienzo AG; Mollan K; Fletcher CV; Margolis DM; Bastow B; Thal G; Woodward W; Godfrey C; Wiegand A; Maldarelli F; Palmer S; Coffin JM; Mellors JW; Swindells S
J Infect Dis; 2009 Mar; 199(6):866-71. PubMed ID: 19191590
[TBL] [Abstract][Full Text] [Related]
53. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
Marinaro L; Calcagno A; Ripamonti D; Cenderello G; Pirriatore V; Trentini L; Salassa B; Bramato C; Orofino G; D'Avolio A; Rizzi M; Di Perri G; Rusconi S; Bonora S
J Clin Virol; 2017 Feb; 87():30-36. PubMed ID: 27992788
[TBL] [Abstract][Full Text] [Related]
54. Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.
Charpentier C; Piketty C; Laureillard D; Tisserand P; Si-Mohamed A; Weiss L; Bélec L
Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):129-33. PubMed ID: 21559766
[TBL] [Abstract][Full Text] [Related]
55. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Kravchenko AV
Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
[TBL] [Abstract][Full Text] [Related]
56. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
[TBL] [Abstract][Full Text] [Related]
57. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Calin R; Paris L; Simon A; Peytavin G; Wirden M; Schneider L; Valantin MA; Tubiana R; Agher R; Katlama C
Antivir Ther; 2012; 17(8):1601-4. PubMed ID: 22941896
[TBL] [Abstract][Full Text] [Related]
58. Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.
Jansen K; Sönnerborg A; Brockmeyer N; Thalme A; Svedhem V; Dupke S; Eychenne JL; Nakonz T; Jimenez-Exposito MJ; Pugliese P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):564-73. PubMed ID: 23016535
[TBL] [Abstract][Full Text] [Related]
59. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
[TBL] [Abstract][Full Text] [Related]
60. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.
Vispo E; Barreiro P; Maida I; Mena A; Blanco F; Rodríguez-Novoa S; Morello J; Jimenez-Nacher I; Gonzalez-Lahoz J; Soriano V
HIV Clin Trials; 2010; 11(4):197-204. PubMed ID: 20974575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
